Retrospective Evaluation of Patients with Achondroplasia Receiving Vosoritide Treatment: A Single-Center Experience

Abstract excerpt

<title>Abstract</title> <p>Purpose Vosoritide, a recombinant C-type natriuretic peptide analog, is the first targeted pharmacological therapy developed for achondroplasia. This study aimed to evaluate changes in annualized growth velocity, height, weight, body mass index z-score, arm span, sitting height-to-height ratio, and head circumference, as well as treatment-related adverse effects, in children with achond...

Topics

Open a Topic to create a Post that cites this publication.

• Achondroplasia
• Adolescent
• Child
• Child, Preschool
• Infant
• Mutation
• Neprilysin
• Receptor, Fibroblast Growth Factor, Type 3

Identifiers and source

Literature Corpus work

a552b294-ddfe-5114-87f6-8f3a4c62a122

DOI

10.21203/rs.3.rs-7982896/v1